Fixed-dose combination and single active ingredient drugs: a comparative cost analysis
Jing Hao1, Rosa Rodriguez-Monguio1, Enrique Seoane-Vazquez2,3
1a 1 School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA.
Expert Review of Pharmacoeconomics & Outcomes Research
|July 16, 2015
Summary
Fixed-dose combination (FDC) drugs often cost more than their individual components. Pricing varies by drug type, approval year, and generic availability, impacting healthcare costs.
Area of Science:
- Pharmaceutical economics
- Drug pricing analysis
- Regulatory science
Background:
- Fixed-dose combination (FDC) drugs combine two or more active pharmaceutical ingredients into a single dosage form.
- Understanding the economic implications of FDCs is crucial for healthcare providers and patients.
- The US Food and Drug Administration (FDA) approves various FDC formulations.
Purpose of the Study:
- To evaluate the pricing structure of FDA-approved FDCs.
- To compare the prices of FDCs with the sum of their individual active ingredients.
- To identify factors influencing price differences.
Main Methods:
- Data sourced from FDA Orange Book and Drugs@FDA databases.
- Average Wholesale Price (AWP) unit prices obtained from The Red Book.
- Analysis of 117 FDA-approved FDCs and their constituent single drugs.
Main Results:
- FDCs showed an average AWP difference of 84.9% compared to the sum of single drugs.
- Price differences varied significantly across therapeutic classes (p < 0.001).
- FDCs with generic single ingredients were priced higher (95.1%) than those without (83.3%).
Conclusions:
- FDC pricing is influenced by therapeutic class, FDC approval year, and generic availability.
- Significant price premiums exist for FDCs over individual components.
- Further research into FDC pricing strategies and their economic impact is warranted.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:01Dosage Regimen: Fixed Dose
2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
01:22Dose-Response Relationship: Potency and Efficacy
7.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
7.5K
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
337
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
337
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
359
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
359